9823 Capital’s Design Therapeutics DSGN Stock Holding History

9823 Capital’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,197	Closed	-$180K	–	52
2025 Q4	$180K	Buy	+19,197	New	+$150K	0.12%	50

Other funds holding DSGN

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

9823 Capital's DSGN Position: Q1 2026 in Review

9823 Capital sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 19,197 shares — an estimated $180K sold.

9823 Capital first reported a position in DSGN in Q4 2025 and held it in 1 quarter. The position peaked at $180K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

9823 Capital reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 19,197 Design Therapeutics shares in Q1 2026, an estimated $180K.
9823 Capital first reported a position in Design Therapeutics in Q4 2025 and held it in 1 quarter.
9823 Capital's Design Therapeutics position peaked at $180K in Q4 2025.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.